‘Baby brain' is real. 3 things to know about what's happening to your brain
Pregnancy is one of the three Ps (puberty, pregnancy and perimenopause), a time when a person's brain undergoes physical changes due to hormones. d3sign//File via CNN Newsource
Science has pretty well established that the brain isn't static; it changes and adapts throughout our lives in response to life events in a process called neuroplasticity.
Researchers are discovering this is especially true of female brains, which get remodeled significantly during the three Ps: puberty (as do the brains of adolescent males), pregnancy and perimenopause.
All three transitions are a frequent butt of pop-culture jokes: the sulky, risk-taking teenager who only wants to be with friends; the scattered mom-to-be who leaves her cell phone in the fridge and can't remember where she parked the car; and the hormonal middle-aged woman who can't focus and spontaneously combusts with hot flashes.
But far from being laughable, these behavioral stereotypes are the external manifestations of big internal shifts, many of them linked to the effects of fluctuating hormones on the brain.
Cognitive neuroscientist Laura Pritschet, a postdoctoral fellow in the department of psychiatry at the University of Pennsylvania, is fascinated by how female hormones, including estrogen and progesterone, affect the brain's organization and functioning.
'The reason I chose that field is because I was a budding neuroscientist as an undergrad, interested in brain networks and obsessing over how intricate everything was in the brain to simply allow us to have a personality or remember things,' Pritschet told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently, on his podcast Chasing Life.
'At the same time in my personal life, I was surrounded by menopausal women who were talking about their cognitive complaints and their attention issues,' she said. 'I thought we've got to connect these two together and understand this more.'
Pritschet even volunteered as a 'guinea pig' during graduate school, having her brain scanned and blood drawn for 30 days, across two complete reproductive cycles (both on and off birth control pills), to begin to answer the question of how the day-to-day fluctuations in hormones relate to the day-to-day changes in the brain.
Around this time, other researchers were studying what happens in the brain during pregnancy, Pritschet said, looking at the brain before and after gestation. They found many changes, but because the studies took a snapshot approach, many questions were left unanswered.
'If there's a 3 to 5% decrease in total gray matter volume, when is that occurring (during pregnancy), and how is it occurring?' Pritschet asked. 'We're missing huge gaps in what we call this metamorphosis.
'We know that the 40-week gestational window leads to these body adaptations to support the development of the fetus: We have increased plasma volume, immune function change, metabolic rate, oxygen consumption,' she said. 'What does this trajectory look like over gestation?'
To find out, Pritschet and her team tracked the brain changes in one woman, using MRI and blood draws, from pre-conception and fertility treatment throughout her pregnancy to two years postpartum. Their findings were published in the journal Nature Neuroscience in September.
'We saw this reduction in gray matter volume pretty much across the whole brain,' Pritschet explained. 'We saw increased white matter microstructure and ventricle size.' (Quick anatomy lesson: The brain is made up of gray and white matter. Gray matter is where most of the brain's thinking and processing takes place. White matter helps connect the different brain areas, allowing them to communicate with one another.)
'The inflection point was birth,' Pritschet said. 'We saw that those reductions persisted into postpartum, with slight recovery, meaning that certain areas of the brain showed this rise in gray matter volume in early postpartum. Others did not.'
Pritschet said this 'choreographed dance between major features of our brain' is in one respect a physical adaptation to the increased blood flow and swelling that comes with pregnancy.
Additionally, the changes may also be a preparation for the next stage: parenting.
'It's a fine-tuning of circuits,' she explained. 'We know that pregnancy is the lead-up to this time in your life where there's a lot of behavioral adaptation that has to occur, and new cognitive demands, and a new cognitive load.
'And so the idea here is that there is this pruning or this delicate rewiring to make certain networks or to make communication in the brain more efficient to meet the demands that are going to have to occur,' Pritschet said.
This theory is supported by earlier work. 'The first pinnacle papers that came out looking at neuroanatomy in human women from preconception to postpartum found that degree of change in gray matter volume — that sort of reduction — correlated with various … maternal behaviors (such as bonding). Again, that's all correlation,' she said.
'That's an area we need to do a lot more research on, and it needs a lot of context,' she said. 'But you can expect that if there's fine-tuning in these circuits that underlie cognitive or behavioral process, that the more fine-tuning it undergoes, the better performance you're going to have. That's the idea — but it's so much more complicated than that.'
What happens to the brain during pregnancy? Pritschet offers these three insights.
The only constant is change
The body is the outward sign of a lot of inner upheaval.
'Pregnancy is a transformative time in a person's life where the body undergoes rapid physiological adaptations to prepare for motherhood,' Pritschet said via email. 'But pregnancy doesn't just transform the body — it also triggers profound change to the brain and reflects another critical period of brain development.'
She called this remodeling an often-overlooked period of brain development that takes place well into a woman's adulthood.
How alarmed should women be?
Less gray matter may not sound very positive, but it happens for a reason.
'Despite what one might think, these reductions are not a bad thing, and in fact, are to be expected,' Pritschet said, noting that some of the losses are eventually regained. 'This change could indicate a 'fine-tuning' of brain circuits, not unlike what happens to all young adults as they transition through puberty and their brain becomes more specialized.'
These changes could also be a response to the high physiological demands of pregnancy itself, she said, 'showcasing just how adaptive the brain can be.'
These changes could affect future health and behavior
Mapping these changes could open the door to understanding an array of other neurological and behavioral outcomes including postpartum depression, headaches, migraines, epilepsy, stroke and parental behavior.
'The neuroanatomical changes that unfold during (pregnancy) have broad implications for understanding vulnerability to mental health disorders … and individual differences in parental behavior,' said Pritschet.
It may even provide critical insight into how the brain changes over a lifespan, she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
38 minutes ago
- National Post
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Article content GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency 1 U.S. Commercialization of GAMMAGARD LIQUID ERC Projected to Begin in 2026 Company Announces Future Manufacturing Discontinuation End Date for Takeda's First-Generation Low-IgA Product, A Freeze-Dried Formulation in Company's Differentiated Immunoglobulin Portfolio of Ready-to-Use Liquids 2 Article content OSAKA, Japan & CAMBRIDGE, Mass. — Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administration burden for patients and their health care providers by eliminating the need for reconstitution and can be administered intravenously or subcutaneously. 1 'The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the lowest IgA content of any ready-to-use liquid immunoglobulin therapy, and can be administered intravenously or subcutaneously,' said Kristina Allikmets, senior vice president and head of Research & Development for Takeda's Plasma-Derived Therapies Business Unit. 'GAMMAGARD LIQUID ERC uses the same state-of-the-art manufacturing process as our other ready-to-use liquid immunoglobulin formulations and is aligned with our forward-looking strategy to prioritize reliable supply while offering a broad range of immunoglobulin therapies to address varied patient needs.' Article content With this approval, Takeda continues to be the only manufacturer of IG therapy with low IgA content less than or equal to 2 µg/mL in a 10% solution. 1 It is anticipated that commercialization of GAMMAGARD LIQUID ERC will begin in the U.S. in 2026, followed by the European Union in 2027, where GAMMAGARD LIQUID ERC is approved by the European Medicines Agency (EMA) as DEQSIGA ®. 3 The timeline to commercial launch is consistent with the time it takes to ramp up manufacturing and supply for plasma-derived therapies. Article content In parallel to this approval, and after thorough analysis, Takeda has decided to discontinue GAMMAGARD S/D [Immune Globulin Intravenous (Human)] IgA less than 1 µg/mL in a 5% solution, the company's first-generation low IgA product. 2 As the only lyophilized (freeze-dried) preparation in Takeda's IG portfolio, GAMMAGARD S/D uses a different, older manufacturing process. For GAMMAGARD S/D, this process is no longer able to reliably meet the future needs of the patient community. Therefore, Takeda has informed the FDA and other health authorities that manufacturing of GAMMAGARD S/D will be discontinued at the end of December 2027. Beyond that date, Takeda intends to maintain GAMMAGARD S/D inventory until it is depleted or expired. Article content 'We understand the impact that this news may have on patients who currently rely on GAMMAGARD S/D for their treatment,' said Kristina Allikmets. 'We are communicating this information now to allow time for patients to work closely with their health care teams to develop alternative treatment plans.' Article content GAMMAGARD LIQUID ERC is a ready-to-use liquid immunoglobulin therapy with an IgA content of less than or equal to 2 µg/mL in a 10% solution to be administered intravenously or subcutaneously. It is indicated in the United States as replacement therapy for primary immunodeficiency (PI) in people two years of age and older. Article content 1 Article content GAMMAGARD LIQUID ERC shares its manufacturing process with GAMMAGARD LIQUID [Immune Globulin Infusion (Human)], with the modification of parameters in a single process step to improve IgA reduction. This enhanced removal capability (ERC) results in a product with IgA less than or equal to 2 µg/mL in a 10% solution. 1 While GAMMAGARD LIQUID ERC is not indicated specifically for IgA sensitivity in people with primary immunodeficiency, it may be an appropriate option for them based on their physician's clinical judgment. GAMMAGARD LIQUID ERC is contraindicated in patients with a history of severe systemic hypersensitivity or anaphylactic reactions to the product. It also carries warnings and precautions regarding the potential for severe hypersensitivity reactions, including in patients who have previously tolerated immune globulin products. Despite containing low levels of IgA (≤2 µg/mL in a 10% solution), the risk of anaphylaxis remains. 1 About GAMMAGARD S/D GAMMAGARD S/D is lyophilized (freeze-dried) immunoglobulin therapy with IgA content less than 1 µg/mL in a 5% solution for intravenous use only. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years and older. GAMMAGARD S/D is also indicated for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell CLL, for the treatment of adult patients with chronic immune thrombocytopenic purpura (ITP) to increase platelet count and to prevent and/or to control bleeding, and for the prevention of coronary artery aneurysms associated with Kawasaki syndrome in pediatric patients. 2 About Primary Immunodeficiency (PI) Primary immunodeficiency (PI) is a group of more than 550 rare and chronic disorders, where a part of the body's immune system is missing or does not function the way it should. 4 These conditions result from genetic mutations, which are usually inherited. 5 The symptoms of PI vary and can include frequent and/or persistent infections and unusual autoimmunity, often leading to prolonged periods of misdiagnosis despite consultations with multiple specialists. 6 In the United States, PI affects about 1 in 1,200 people. 7 GAMMAGARD LIQUID ERC, GAMMAGARD LIQUID and GAMMAGARD S/D U.S. Important Safety Information WARNING: THROMBOSIS Thrombosis may occur with immune globulin (IG) products, including GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC and GAMMAGARD S/D. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. For patients at risk of thrombosis, administer GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC and GAMMAGARD S/D at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. WARNING: RENAL DYSFUNCTION and ACUTE RENAL FAILURE Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products, including GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC and GAMMAGARD S/D. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMMAGARD LIQUID, GAMMAGARD LIQUID ERC and GAMMAGARD S/D do not contain sucrose. Contraindications GAMMAGARD LIQUID is contraindicated in patients with a history of anaphylactic or severe systemic hypersensitivity reactions to human IG, and IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG. Anaphylaxis has been reported with intravenous (IV) use of GAMMAGARD LIQUID. GAMMAGARD LIQUID ERC and GAMMAGARD S/D are contraindicated in patients with a history of anaphylactic or severe systemic hypersensitivity reactions to the administration of GAMMAGARD LIQUID ERC and GAMMAGARD S/D. Warnings and Precautions Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. Severe hypersensitivity reactions and anaphylactic reactions with a fall in blood pressure have occurred in patients receiving GAMMAGARD S/D, including patients who tolerated previous treatments with GAMMAGARD S/D, even though it contains low levels of IgA. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis. Article content Renal Dysfunction/Failure: Article content GAMMAGARD LIQUID Article content and Article content GAMMAGARD S/D Article content . Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation. Article content may occur. It is critical to distinguish true hyponatremia from pseudohyponatremia because certain treatments may lead to volume depletion, a further increase in serum viscosity, and a predisposition to thromboembolic events. Article content Thrombosis: Article content Has been reported to occur following treatment with IG products and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. Article content Aseptic Meningitis Syndrome: Article content Has been reported with use of IG. Article content Article content Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae. The syndrome usually begins within several hours to two days following IG treatment Article content Hemolysis: GAMMAGARD LIQUID Article content , Article content GAMMAGARD LIQUID ERC, Article content and Article content GAMMAGARD S/D Article content contain blood group antibodies, which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing. Article content Transfusion-Related Acute Lung Injury: Article content GAMMAGARD LIQUID Article content . Article content Article content Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support. Article content Transmittable Infectious Agents: Article content Because Article content GAMMAGARD LIQUID Article content , Article content GAMMAGARD LIQUID ERC, Article content and Article content GAMMAGARD S/D Article content are made from human plasma, they may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No confirmed cases of viral transmission or variant Creutzfeldt-Jakob disease (vCJD) have been associated with Article content GAMMAGARD LIQUID. Article content positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies. Article content Alterations in serum sodium levels Article content GAMMAGARD S/D Article content . In patients on a low sodium diet, calculate the amount of sodium from Article content GAMMAGARD S/D Article content when determining dietary sodium intake. Article content Adverse Reactions Article content GAMMAGARD LIQUID Article content IV administration: Article content The serious adverse reaction seen during IV clinical trials was aseptic meningitis. The most common adverse reactions observed in ≥5% of patients in clinical trials were headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur. Article content Subcutaneous administration: Article content The most common adverse reactions observed in ≥5% of patients in clinical trials were infusion site (local) event (rash, erythema, edema, hemorrhage, and irritation), headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, and pain in extremity. Article content GAMMAGARD LIQUID ERC Article content The safety of GAMMAGARD LIQUID ERC in patients with primary humoral immunodeficiency (PI) is supported by two clinical studies conducted on GAMMAGARD LIQUID. No clinical studies have been conducted using GAMMAGARD LIQUID ERC. Article content IV administration: Article content The most common adverse reactions observed in ≥5% of patients in study 1 were headache, fatigue, pyrexia, chills, nausea, pain in extremity, diarrhea, migraine, vomiting, dizziness, urticaria, cough, asthma, oropharyngeal pain, infusion site extravasation, arthralgia, rash, myalgia, pruritis, and cardiac murmur. Article content Subcutaneous administration: Article content The most common adverse reactions observed in ≥5% of patients in study 2 were infusion site (local) event, headache, pyrexia, fatigue, heart rate increased, abdominal pain upper, vomiting, arthralgia, nausea, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous ulcer, migraine, oropharyngeal pain, and pain in extremity. Article content GAMMAGARD S/D Article content The most common adverse reactions observed in ≥5% of clinical trial patients during or within 48 hours of infusion were headache, nausea, chills, fatigue, pyrexia, upper abdominal pain, diarrhea, back pain, infusion site pain, hyperhidrosis, and flushing. Article content The most serious adverse reactions reported postmarketing include renal failure, thrombotic events (myocardial infarction, cerebrovascular accidents, and pulmonary embolism), anaphylactic shock, aseptic meningitis, and hemolysis. Article content Drug Interactions Article content Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella). Article content For Full U.S. Prescribing Information for GAMMAGARD LIQUID, please visit: Article content For Full U.S. Prescribing Information for GAMMAGARD LIQUID ERC, please visit: Article content Article content For Full U.S. Prescribing Information for GAMMAGARD S/D, please visit: Article content For European Union Summary of Product Characteristics for DEQSIGA, please visit: Article content About Takeda Article content Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Article content . Article content For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. Article content The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Article content Forward-Looking Statements Article content This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: Article content or at Article content Article content . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Article content Medical Information Article content This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Article content Article content Article content Article content Article content Contacts Article content Media Contacts: Article content Article content U.S. Media Article content Article content Taryn Corbino Article content Article content Article content Article content Article content


Globe and Mail
9 hours ago
- Globe and Mail
I remember Marc Garneau
The Stars and Stripes on the flagpole at the front of the Johnson Space Center is enormous, as you'd expect from a major American institution. I had been at Johnson for a couple of days, as a reporter covering the shuttle flight of Canadian astronaut Steve MacLean, and I remember being struck by the sheer size of the place – some 100 buildings on more than 1,600 acres of land. And, of course, that giant, brash flag. I first met Marc Garneau, Canada's first astronaut, on Oct. 24, 1992, at JSC, where he was with the Canadian Space Agency. MacLean's shuttle had been launched from Kennedy Space Center two days earlier and I had flown across the U.S. to follow the flight from mission control at JSC. Marc Garneau, first Canadian in space, remembered for aspirations he held for his country That Saturday evening, there was also some baseball being played. The Toronto Blue Jays, leading the World Series with the Atlanta Braves 3-2, were in the Georgia city for Game 6. After filing my report for the day to the Toronto Star, I joined other journalists and members of the Canadian Space Agency in a hotel room to watch the game. Garneau, as I recall, was not expected, owing to pressure of work on the mission, but showed up anyway, a couple of innings into the game. Someone had organized a betting pool, in which you picked a number. If that number turned out to equal the sum of the runs scored in the game, you took the kitty. As it happened, both Garneau and I had 7; the Jays won the game 4-3 to take their first World Series so Garneau and I shared the small prize. The party broke up soon after the game ended. The shuttle mission was still under way and we all had work the next day. That Sunday, as I drove into the JSC complex, I noticed an oddity. Atop the flagpole, above the U.S. flag, was a small red and white banner. Somehow, the Maple Leaf had been hoisted during the night. And because it was Sunday, with only the shuttle mission staff on the premises, it stayed there all day. When it comes to space, Canada has always reached for the stars I met Garneau a couple of times later, in the course of my work as The Star's science reporter, and asked him about the flag. He said he couldn't possibly comment. You can find more obituaries from The Globe and Mail here. To submit a memory about someone we have recently profiled on the Obituaries page, e-mail us at obit@


Globe and Mail
14 hours ago
- Globe and Mail
Anosh Laboratory Technologies Unveils Advanced Platform to Improve Diagnostic Accuracy and Prevent Testing Fraud
Chicago, Illinois--(Newsfile Corp. - June 29, 2025) - Anosh Laboratory Technologies has announced the upcoming release of a next-generation diagnostic platform developed to enhance laboratory testing precision and strengthen fraud prevention across the clinical testing ecosystem. Dr. Anosh Ahmed To view an enhanced version of this graphic, please visit: The proprietary system-under development since 2020-was initiated under the leadership of Dr. Anosh Ahmed, founder of Anosh Laboratory Technologies, in direct response to the operational gaps exposed during the COVID-19 pandemic. Designed to support both public and private sector laboratories, the technology combines high-throughput testing capabilities with built-in compliance, real-time data verification, and traceability controls. "Our team set out to close critical gaps in laboratory testing infrastructure-specifically around accuracy, accountability, and fraud detection," said Dr. Anosh Ahmed. "This platform reflects five years of focused R&D and cross-functional collaboration." Built for scalability, the system is compatible with existing lab workflows and optimized for rapid deployment in infectious disease and high-volume diagnostic environments. Its modular architecture allows for customization based on lab size, regulatory requirements, and test volumes. A comprehensive technical white paper detailing the system design, performance metrics, and application roadmap will be released in the coming weeks. Regulatory submissions are expected to follow shortly thereafter. The launch aligns with Dr. Anosh Ahmed's ongoing commitment to advancing healthcare infrastructure through innovation, transparency, and operational integrity. His work through Anosh Laboratory Technologies continues to bridge clinical needs with long-term system sustainability. This release marks a key milestone in Anosh Laboratory Technologies' broader mission to modernize diagnostic systems and reinforce trust across healthcare delivery. About Anosh Laboratory Technologies Anosh Laboratory Technologies is a Chicago-based diagnostics and health technology company founded by Dr. Anosh Ahmed, focused on advancing lab systems through innovation, compliance automation, and scalable solutions for global health challenges.